Regenerex Pharma (RGPX) Accounts Payables (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Accounts Payables data on file, last reported at $218748.0 in Q3 2025.

• Accounts Payables for Q3 2025 came in at $218748.0, up 41.48% year-over-year; the trailing twelve-month figure through Sep 2025 was $218748.0 (up 41.48% YoY), and the FY2025 annual result was $197673.0, up 69.3% from the prior year.
• Accounts Payables grew to $218748.0 in Q3 2025 per RGPX's latest filing, from $171268.0 in the prior quarter.
• Over five years, Accounts Payables peaked at $218748.0 in Q3 2025 and troughed at $47813.0 in Q4 2021.
• A 5-year average of $105062.3 and a median of $78950.0 in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2021 and 2024: Accounts Payables fell 18.52% in 2021, then soared 133.92% in 2024.
• A 5-year view of Accounts Payables shows it stood at $47813.0 in 2021, then jumped by 38.3% to $66125.0 in 2022, then advanced by 19.4% to $78950.0 in 2023, then soared by 133.92% to $184681.0 in 2024, then rose by 18.45% to $218748.0 in 2025.
• Business Quant data shows RGPX's Accounts Payables at $218748.0 in Q3 2025, $171268.0 in Q2 2025, and $197673.0 in Q1 2025.